A nanoswitch molecule and its control of activated solid tumor-targeted CAR-T cells

A CAR-T and nanoswitch technology, applied in the field of tumor immunology, can solve the problems of complex CAR-T design, production and preparation, and large-scale clinical application, and the lack of solid tumor-specific surface antigens, so as to solve off-target effects. , the effect of prolonging the half-life of the drug

Active Publication Date: 2021-07-09
NANJING DRUM TOWER HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The main ideas for controlling the off-target effect of CAR-T in solid tumors include: 1. Find new targets or design multi-target activation of CAR-T cells: the ideal CAR-T target should satisfy the following requirements: ① located on the surface of tumor cells; ② located on the surface of specific tumor cells High surface expression ③ It is not expressed in normal tissues, but no solid tumor-specific surface antigen that fully meets the above requirements has been found; 2. Control CAR-T inactivation, including introducing herpes simplex virus thymidine kinase (HSV-tk), Fas intracellular domain (ΔFAS), iCasp9 and other artificially synthesized death control switches, but none of the above methods can fundamentally solve the problem of non-specific activation of CAR-T, and the complex design of CAR-T leads to production and large-scale Scale clinical application poses difficulties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A nanoswitch molecule and its control of activated solid tumor-targeted CAR-T cells
  • A nanoswitch molecule and its control of activated solid tumor-targeted CAR-T cells
  • A nanoswitch molecule and its control of activated solid tumor-targeted CAR-T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The preparation of gelatinase-targeted nanoparticles includes the following four steps:

[0041] Step A) Synthesis of PCL-NH2: Using ε-CL (ε-caprolactone, ε-caprolactone) as raw material, adopting free radical polymerization method to synthesize PCL (polycaprolactone) containing carboxyl group, denoted as PCL-COOH , and then use EDC to aminate the end of PCL-COOH to form PCL with an active amino group, which is denoted as PCL-NH2. The specific reaction is as follows:

[0042]

[0043] Step B) Synthesis of mPEG-PEP: The activated mPEG-NHS reacts with the amino terminal of polyethylene glycol monomethyl ether (mPEG) to synthesize mPEG-PEP. The specific reaction is as follows:

[0044]

[0045] Step C) synthesis of enzyme targeting carrier: in the presence of EDC, DMAP, NHS, the carboxyl group at the end of mPEG-PEP and the amino group at the end of PCL-NH2 react to form mPEG-PEP-PCL diblock copolymer, the Compared with the traditional two-block copolymer mPEG-PCL (...

Embodiment 2

[0048] The preparation of nano-switch molecules, the nano-switch molecules are tumor-targeted nanoparticles loaded with switch molecules, which are constructed by double emulsification-volatility method, specifically including the following steps:

[0049] Step 1) dissolving the hydrophobic switch molecule and the tumor-targeting nanocarrier in a dichloromethane solution to form an organic phase, a mixed solution A;

[0050] Step 2) Add mixed solution A to the first external aqueous phase containing 3% polyvinyl alcohol and use ultrasonic emulsification technology to fully mix to form mixed solution B, wherein the mPEG-PEP-PCL diblock copolymer is self-contained in the aqueous phase Assembled into polymer nanoparticles with the hydrophilic end outward and the hydrophobic end inward;

[0051] Step 3) adding the mixed solution B into the second external aqueous phase containing 1% polyvinyl alcohol and fully mixing it with ultrasonic emulsification technology to form the mixed s...

Embodiment 3

[0057] The preparation of solid tumor-targeted CAR-T cells includes the following steps:

[0058] 1) Preparation of nano-switch molecules: using the nano-switch molecules prepared in Example 2;

[0059] 2) Construct and amplify the assembled CAR-T plasmid: T2A gene (T2A gene sequence is shown in SEQ ID NO.), FRB sequence (FRB sequence is shown in SEQ ID NO.2), FKBP sequence using gene recombination technology (FKBP sequence shown in SEQ ID NO.3) and the ScFv segment targeting solid tumors (ScFv segment sequence shown in SEQ ID NO.4) were introduced into the CAR-T plasmid to construct an assembled CAR-T plasmid (pDonor-SB- HER2-4-1BB-FKBP-DPA10-FRB-EGFP plasmid, such as figure 1 shown), using Escherichia coli DH5α as the carrier to amplify the assembled CAR-T plasmid;

[0060] Among them, T2A gene sequence: 5'-CGGAAGCGGAGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGACCTA-3'(SEQ ID NO.1);

[0061] FKBP序列:5’-GGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTG...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a nano-switch molecule and solid tumor-targeted CAR-T cells controlled and activated by the same. The solid-tumor-targeted CAR-T cells are prepared by the following steps: 1) Preparation of nano-switch molecules: double emulsification-volatile 2) Construction of an assembled CAR-T plasmid: the T2A element, FRB, FKBP sequence and the ScFv segment targeting solid tumors were introduced into the CAR-T plasmid by genetic recombination ; 3) Preparation of assembled CAR-T cells: transfection of assembled CAR-T plasmids into T lymphocytes; 4) Preparation of solid tumor-targeted CAR-T cells: assembly of CAR-T cells endocytosis of nano-switch molecules. In the present invention, by using tumor-targeting nanoparticles to load switch molecules, the switch molecules can be specifically aggregated in tumor tissues, and the switch molecules are connected to FKBP and FRAP of CAR-T, so that the two parts of CAR-T can be combined to have attack activity. It can fundamentally solve the problem of off-target effects of CAR‑T cells.

Description

technical field [0001] The invention belongs to the technical field of tumor immunology, and in particular relates to a nano-switch molecule and solid tumor-targeted CAR-T cells controlled and activated by the same. Background technique [0002] CAR-T therapy (Chimeric Antigen Receptor T-Cell Immunotherapy, Chimeric Antigen Receptor T-cell Immunotherapy) has made a major breakthrough in the treatment of leukemia, bringing new hope to patients with certain blood cancers. However, CAR-T therapy faces obstacles when it is applied to solid tumors. The most critical reason is that the targets of CAR-T in solid tumors are expressed in a small amount in normal tissues, so CAR-T can non-specifically attack normal tissues. Serious off-target effects have been caused, and related deaths have been reported. [0003] The preparation method of CAR-T cells is to transfect CAR gene plasmids into T lymphocytes to make them into CAR-T cells. The transfection methods include virus transfecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/62A61K47/60A61K47/59A61K9/14A61K31/365A61K31/436A61K39/00A61P35/00C12N5/10C12N15/867
CPCA61K9/146A61K31/365A61K31/436A61K47/593A61K47/60A61K47/62A61P35/00A61K39/001111C07K14/7051C07K16/30C12N5/0636C12N15/86C12N2510/00C12N2740/15043A61K2300/00
Inventor 李茹恬刘宝瑞
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap